Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 16-week, double-blind, placebo-controlled, randomised, parallel-group, multicentre, international study to evaluate the efficacy and safety of 40 mg/day KW-6002 (istradefylline) and that of entacapone versus placebo as treatment for Parkinson's disease in patients with motor response complications on levodopa therapy

Trial Profile

A 16-week, double-blind, placebo-controlled, randomised, parallel-group, multicentre, international study to evaluate the efficacy and safety of 40 mg/day KW-6002 (istradefylline) and that of entacapone versus placebo as treatment for Parkinson's disease in patients with motor response complications on levodopa therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Istradefylline (Primary) ; Entacapone
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin; Kyowa Kirin
  • Most Recent Events

    • 07 Jun 2011 New source identified and integrated (European Clinical Trials Database).
    • 27 Nov 2005 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top